Company intelligence / Profile preview
Gene Surgery LLC
Russia
- Ownership
- Private
- Development stage
- Other
01
Overview
Gene Surgery LLC has completed a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of its gene therapy candidate Stimotimagene copolymerplasmid in patients with advanced-stage solid tumors. The study involved different dosing regimens combined with Cymeven® (Ganciclovir) infusions. No detailed efficacy results are publicly available as of January 2025.
- Therapeutic areas
- GastroenterologyOncologyDermatology
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships disclosed as of January 2025.
Beyond the preview
Go deeper on Gene Surgery LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gene Surgery LLC.